Breast cancer generally occurs in women, but men can get the disease too.
According to the largest real-life study yet to investigate treatment and outcomes in men with breast cancer and two further studies reported at annual congress of the European Society for Medical Oncology – ESMO 2018, confirms that there is growing evidence that drugs approved for the treatment of breast cancer in women are also effective and well tolerated for the treatment for men with breast cancer. 
The most common types of breast cancer in men are ductal carcinoma in situ, invasive ductal carcinoma, and invasive lobular carcinoma. Most breast cancers are carcinomas. These cancers are often a type of carcinoma called adenocarcinoma which starts in cells that make glands (glandular tissue). Breast adenocarcinomas start in the ducts (the milk ducts) or the lobules (milk-producing glands). However, there are also other, less common, types of breast cancers such as sarcomas, phyllodes, Paget?s disease and angiosarcomas which start in the cells of the muscle, fat, or connective tissue.
Approximately one in every 100 cases of breast cancer (1%) occurs in men. However, there have been few prospective studies in men, and clinical trials of breast cancer treatments have often excluded men. As a result, treatment recommendations are largely extrapolated from the results of clinical trials in women .
To learn more about the treatment of breast cancer in men researchers analyzed clinical data collected by the Epidemiological Strategy and Medical Economics Metastatic Breast Cancer (ESME MBC) platform. The research was conducted between January 2008 and December 2014.
This ESME MBC database collects real-life data from 18 French Comprehensive Cancer Centers for all patients newly diagnosed with metastatic breast cancer starting at least one treatment.
Men vs. women
Researchers retrieved the data for men with metastatic breast cancer included in the database and compared their treatment and outcome with those in women. They found 149 men from the total of 16,701 patients (0.89%).
The men were slightly older than the women (mean age 68.1 years vs 60.6 years, p<0.0001). Just over three-quarters of the men (105/149; 78.4%) had hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2) negative breast cancer, which was a slightly higher proportion than in women (65.6%, p=0.0019).
Results showed men received similar treatments to women with metastatic breast cancer. Just under half of those with HR+/HER2-negative breast cancer (45/105, 42.9%) received frontline hormonal therapy: tamoxifen (20/45), aromatase inhibitor + luteinizing hormone releasing hormone (LHRH) analogues (18/45) or others (7/45).
Their median progression-free survival was 9.8 months, which was similar to that seen in a matched group of women (13.0 months, p=0.8) with the same age, breast cancer histology and grade, location of metastasis and adjuvant treatment.
One in four men with HR+/HER2- breast cancer (29/105, 27.6%) were treated with front-line chemotherapy. Their median progression-free survival was also similar to a matched group of women receiving chemotherapy (6.9 months vs 6.3 months, hazard ratio 1.24, 95% confidence interval 0.69-2.23). Overall survival for the whole population of men included in the database was also similar to that for women (41.8 months vs 34.9 months, p=0.745).
“We have reported on one of the biggest series of men with metastatic disease, with comprehensive data on their management and outcome with different types of treatment,? noted study author Jean-S?bastien Fr?nel, MD, PhD student from the Institut de Cancerologie de l’Ouest, Nantes, France.
“We found that most of the men with HR+/HER2- metastatic disease had received frontline chemotherapy and around 40% had received hormonal therapy. Most of the patients receiving hormonal therapy were treated with tamoxifen and the remainder received aromatase inhibitors. But few patients received aromatase inhibitors plus LHRH analogues despite some guidelines recommending that they should be given in combination,” Fr?nel added.
“The progression-free survival provided by chemotherapy or hormonal therapy was similar in men as in women.?
In terms of clinical implications, Fr?nel suggested that “Hormonal therapy should be given to men with HR+/HER2- metastatic breast cancer in the absence of visceral crisis.”
He also added that oncologists should be aware that aromatase inhibitors should not be given without LHRH analogues. The study is continuing and will next assess the prevalence of BRCA mutation in the patient population.
Tumor characteristics and outcome in men
“A recent study looked at tumor characteristics and outcome in a large cohort of men with primary breast cancer but such extensive data on advanced breast cancer in men was missing until now,? said Agnes Jager, a medical oncologist and associate professor at Erasmus Medical University Cancer Institute, Rotterdam, The Netherlands, commenting on the study’s findings.
“This new study shows the prognosis of men and women is similar, which is of great value as this justifies our current clinical practice. We currently treat men with breast cancer in a similar way to women, which is now supported by these data,” she added.
A small number
Jager also noted that although the largest study of its kind, the number of men with breast cancer was still small and data were lacking on the extent of advanced disease, BRAC mutation status and type of chemotherapy.
“[However] more detailed information and longer-term follow-up will indicate whether there are characteristics or prognostic factors that are specific for men, which will allow us to change practice in the future,” Jager further noted.
Results from the first prospective randomised trial to assess different hormonal treatments in men with breast cancer showed that levels of estradiol, a form of the hormone estrogen, decreased steeply with a gonadotrophin releasing hormone analogue (GnRHa) plus tamoxifen or the aromatase inhibitor exemestane but increased with tamoxifen alone measured after a 6 months? treatment period. 
More than 90% of male breast cancer patients have HR+ disease. Tamoxifen is currently the standard of care hormonal therapy but there is limited data on its efficacy and safety in men and little information on other hormone blocking treatments.
The Male-GBG54 study (NCT01638247),?the first prospective, randomized, multicenter trial evaluating the efficacy and safety of different endocrine treatment options in male breast cancer patients, randomised 55 men with breast cancer to hormonal therapy with one of three regimens as adjuvant or metastatic therapy for six months: tamoxifen (20mg per day); tamoxifen + gonadotrophin releasing hormone analogue (GnRHa) (subcutaneous every 3 months); exemestane (25mg/day) + GnRHa.
Tamoxifen blocks estrogen from attaching to hormone receptors on cancer cells while exemestane is an aromatase inhibitor that inhibits estrogen synthesis. The use of GnRH analogues in men with breast cancer is controversial but is based on reducing levels of testosterone when used in combination with aromatase inhibitors or antiandrogens .
Results reported at the annual congress of the European Society for Medical Oncology – ESMO 2018,? showed the median level of estradiol increased by 67% at three months and by 41% at six months in men treated with tamoxifen alone. In contrast, estradiol levels decreased by 85% after three months in men treated with a GnRH analogue plus tamoxifen and by 73% in those receiving a GnRH analogue plus exemestane. Estradiol levels continued to be decreased at six months with GnRH analogues plus tamoxifen or exemestane. These therapies were well tolerated with no safety signals.
The researchers also assessed the impact of treatment on quality of life and sexual function in men with breast cancer treated with hormonal therapy for the first time, using a validated questionnaire (Aging Males? Symptoms Scale Questionnaire) and assessment of erectile function (International Index of Erectile Function). Results showed that tamoxifen had little impact on health-related quality of life or erectile function in men with breast cancer while the combination of GnRH analogue plus exemestane had a major adverse effect on both measures.
“We observed a deep and stable decrease of estradiol in patients receiving the combination of tamoxifen or an aromatase inhibitor plus GnRH for six months of therapy within the Male trial. The suppression of peripheral estradiol is a necessary condition for a therapeutic benefit of endocrine therapy in men with breast cancer when receiving an aromatase inhibitor plus GnRH analogue. Within the tamoxifen monotherapy arm, the estradiol values increased. These changes are known from female breast cancer patients and were expected,” noted ead author Mattea Reinisch, MD, from Klinikum Essen-Mitte, Essen, Germany.
“Tamoxifen monotherapy should be kept as standard hormonal therapy for men with breast cancer. The side-effects are moderate, hardly impairing sexual behavior. The combination with GnRH influenced patients? well-being and erectile function profoundly,” Reinisch added.
“The authors are to be congratulated with a randomised trial in such a rare study population, which must have been a real effort. However, it is regrettable that the estradiol suppression at 3 months was the primary endpoint. Although it is relevant to know whether and to what extent E2 levels change over time during different endocrine treatment strategies, as far as I know E2 suppression at 3 months is neither a validated nor a clinically useful surrogate endpoint for the efficacy of endocrine treatment,” associate professor Agnes Jager said.
“The finding that tamoxifen without an LHRH agonist led to a pronounced increase of E2 levels after 3 and 6 months of treatment is not new, although the degree of the increase is somewhat unexpected,”she said
But she cautioned that the endpoint used in the study did not answer the question of whether an LHRH agonist should be added to tamoxifen in men and further research is needed on this.
“Due to the severe side-effects of LHRH agonists in men and the negative impact on quality of life, clarity about this is of great clinical importance,” Jager added.
Prolonging sensitivity to hormonal therapies
The cyclin dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor) ribociclib plus the aromatase inhibitor letrozole has comparable safety and tolerability as first-line therapy in men with HR+/HER2- advanced breast cancer to that seen in women, according to preliminary results from an international Phase III trial reported at ESMO 2018. 
Most patients with HR+ breast cancer become resistant to hormonal therapies over time so there is a lot of interest in finding treatments to prolong or restore sensitivity. Inhibiting the CDK4/6 has been identified as a potential target for overcoming or delaying resistance to hormonal therapy in advanced HR+/HER2-breast.
The CDK4/6 inhibitor ribociclib is approved for use in combination with an aromatase inhibitor for treating postmenopausal women with HR+/HER2- advanced breast cancer who have received no previous treatment for advanced breast cancer based on results from a trial showing significantly prolonged progression-free survival. However, men were not included in the study.
The international CompLEEment-1 trial included 20 men with HR+, HER2- advanced breast cancer in the first 1008 patients enrolled who completed 56 days of follow-up or discontinued before data cut-off. They were treated on an open-label basis with ribociclib (600mg per day, 3 weeks on/1 week off) plus letrozole (2.5mg/day). Male patients also received concomitant goserelin (3.6mg subcutaneous implant every 28 days). A pre-planned interim analysis was conducted approximately 15 months after the first patient?s first visit for the primary outcome of safety and tolerability.
Results reported at ESMO 2018 showed the most frequent adverse events in men were hot flushes (30.0%), neutropenia (20.0%) and constipation (20.0%). Adverse events of grade 3 severity or higher included neutropenia (4 patients, 20.0%), increased alanine aminotransferase (2 patients, 10%) and increased aminotransferase (1 patient, 5.0%). QT prolongation was infrequent, occurring in 3 men (15.0%) and all events were grade 1 or 2.
Just over one-third (35.0%) of men required dose reduction or interruption due to adverse events, while two men discontinued treatment due to adverse events.
“We can conclude in this sub-population of men that the tolerability and the expected toxicity with ribociclib in men is no different to women. And this increases our confidence in data obtained in large trials with women in order to translate the results and the applicability to men,? explained lead author Claudio Zamagni, MD, Head of Breast and Gynaecological Medical Oncology, Sant?Orsola Malpighi Hospital, Bologna, Italy.
The combination of hormonal therapy plus ribociclib should be considered as an option also for male patients with metastatic HR+ HER2- breast cancer,” Zamagni suggested. He noted that this was the first study to assess the safety of a CDK4/6 inhibitor in men, adding that efficacy data will be reported with longer-term follow-up in the future.
“As expected, there were no major differences in safety compared to previously published toxicity data for women, with the exception of the prevalence of neutropenia,” Jager commenting on the study. She noted that the limitation of the study were the small numbers and the lack of efficacy data at the time of reporting. “This was less frequent compared with female breast cancer patients in the MONALEESA 2 study (NCT01958021; grade 3/4: 20.0% in men vs 59.3% in women),” she said.
Jager suggested that if similar results were shown in other studies, this could be of interest from a mechanistic point of view.
“One of the explanations might be that there is a gender-dependent toxic effect on bone marrow. Alternatively, it could be a reflection of different plasma concentrations of ribociclib in men and women,? Jager suggested.
“If this were the case, efficacy could be lower in man,” she added
“The first step forwards is to compare the outcome between the men and women within the CompLEEment study, as well as cross-comparing with other studies in women,” Jager continued.
“Male breast cancer patients seem to benefit from endocrine therapy to a similar degree as women. Furthermore, these research results add to the current literature suggesting that the addition of GnRH analogues might improve on tamoxifen alone, but studies with clinical endpoints are needed. Lastly, it is urgent that strategies that have proven effective in defering resistance to endocrine therapy in women are explored in men with advanced breast cancer as well, including CDK4/6 inhibitors,” concluded Stefan Zimmerman, MD, Centre Hospitalier Universitaire Vaudois, Switzerland.
 Abstract 294PD_PR ?Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program ? will be presented by Junien Sirieix during the Poster Discussion Session on Monday 22 October, 11:15 to 12:15 (CEST) in Room 14b – ICM. Annals of Oncology, Volume 29 Supplement 8 October 2018
 Abstract 273PD_PR ?Final analysis of the Male-GBG54 study: a prospective multi-centre phase II study evaluating endocrine treatment with either tamoxifen +/- gonadotropin releasing hormone analogue (GnRHa) or an aromatase inhibitor + GnRHa in male breast cancer patients? will be presented by Mattea Reinisch during the Poster Discussion Session on Monday 22 October, 11:15 to 12:15 (CEST) in Room 14b – ICM. Annals of Oncology, Volume 29 Supplement 8 October 2018
 Abstract 293PD_PR ?Ribociclib (RIBO) + letrozole (LET) in male patients (pts) with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC) and no prior endocrine therapy (ET) for ABC: preliminary subgroup results from the phase 2 CompLEEment-1 trial? will be presented by Claudio Zamagni during the Poster Discussion Session on Monday 22 October, 11:15 to 12:15 (CEST) in Room 14b – ICM. Annals of Oncology, Volume 29 Supplement 8 October 2018
 Gradishar, W. J. (2018, March). Breast cancer in men. Online Last accessed October 20, 2018. [Update]
 Giordano SH. Breast cancer in men. N Engl J Med. 2018 Jun 14;378(24):2311-2320. doi: 10.1056/NEJMra1707939.
 Unicancer R&D. ESME Research Program. Epidemiological Strategy and Medical Economic. Academic Real-world Data Platform.
 ESME Research Program | Epidemiological Strategy and Medical Economics Academic Real-world Data Platform | R&D Unicancer. [Slide Presentation]
 Di Lauro L, Pizzuti L, Barba M et al. Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis. Journal of Hematology & Oncology 2015: 8: 53
 Hortobagyi GN, Stemmer SM, Burris HA et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. NEJM 2016; 375: 1738-1745
Last Editorial Review: October 21, 2018
Featured Image: ESMO 2018. Courtesy: ? 2018 European Society for Medical Oncology. Used with permission.
Copyright ? 2010 ? 2018 Sunvalley Communication, LLC. All rights reserved. Republication or redistribution of Sunvalley Communication content, including by framing or similar means, is expressly prohibited without the prior written consent of Sunvalley Communication. Sunvalley Communication shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Onco?Zine, Oncozine and The Onco?Zine Brief are registered trademarks and trademarks of Sunvalley Communication around the world.